论文部分内容阅读
目的探讨分析阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症的临床疗效。方法 100例初发2型糖尿病伴高脂血症患者,随机分为实验组与对照组,每组50例。对照组患者采用阿卡波糖进行治疗,实验组患者采用阿卡波糖联合二甲双胍进行治疗。治疗结束后对两组患者的临床效果进行比较分析,并对两组患者的血糖水平、血脂指标改善情况及患者服药的不良反应发生率进行比较。结果对照组患者显效19例,有效21例,无效10例;总有效率为80%。实验组患者显效25例,有效22例,无效3例;总有效率为94%;实验组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,实验组患者的空腹血糖(FPG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA1c)指标均低于对照组,差异有统计学意义(P<0.01)。实验组患者总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)指标均优于对照组,差异有统计学意义(P<0.01)。实验组与对照组不良反应发生率比较差异无统计学意义(P>0.05)。结论阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症疗效明显,可降低患者的用药不良反应发生率,降血脂效果明显,值得在临床中推广应用。
Objective To investigate the clinical efficacy of acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes with hyperlipidemia. Methods One hundred patients with newly diagnosed type 2 diabetes with hyperlipidemia were randomly divided into experimental group and control group with 50 cases in each group. Patients in the control group were treated with acarbose, and patients in the experimental group were treated with acarbose and metformin. After the treatment, the clinical effects of the two groups were compared and analyzed. The blood glucose level, the improvement of the blood lipid index and the incidence of adverse reactions of the patients in the two groups were compared. Results In the control group, 19 cases were markedly effective, 21 cases were effective and 10 cases were ineffective. The total effective rate was 80%. In the experimental group, 25 cases were markedly effective, 22 cases were effective and 3 cases were ineffective. The total effective rate was 94%. The total effective rate in the experimental group was higher than that in the control group (P <0.05). After treatment, the fasting blood glucose (FPG), 2 h postprandial blood glucose (2 hPG) and HbA1c in the experimental group were lower than those in the control group, with significant difference (P <0.01). The total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) in the experimental group were significantly higher than those in the control group P <0.01). There was no significant difference in the incidence of adverse reactions between experimental group and control group (P> 0.05). Conclusion Acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes with hyperlipidemia has obvious curative effect, which can reduce the incidence of adverse drug reactions in patients with obvious anti-hyperlipidemia and is worth popularizing in clinic.